The Collaborative clinical research network on Friedreich’s ataxia from Montreal is now seeking the participation of a pediatric patient with a diagnosis of Freidreich’s ataxia in order to join the study of natural history! This international network brings together 13 sites working together to advance the treatment and clinical...
Late-onset hereditary dominant episodic ataxia in French Canadians Dr David Pellerin 1, Dr. Mathilde Renaud 2, Mrs. Karine Choquet 1, Prof. Martine Tétreault 3, Mrs. Sylvie Provost 3, Mrs. Marie-Josée Dicaire 1, Dr Roberta La Piana 1, Dr Rami Massie 1, Dr Colin Chalk 1, Dr. Anne-Louise Lafontaine 1, Prof. Marie-Pierre...
This is a review article focusing on the insights into the pathogenesis of this disorder and how those insights are being translated into novel therapeutic approaches. For example, more recently, a role for inflammation has emerged as being important in the pathogenesis of Friedreich ataxia. These findings have led to...
Resume from the Friedreich’s Ataxia News article, Vibration Device, Equistasi, Seen to Aid Movement in Ataxia Patients in Small Study “The study, “A Wearable Proprioceptive Stabilizer For Rehabilitation Of Limb And Gait Ataxia In Hereditary Cerebellar Ataxias: A Pilot Open-Labeled Study,” was published in the journal Neurological Sciences. Equistasi is...
Following correspondence with Health Canada and Santhera, we present the results of the negotiated agreement: Santhera formally commits to offering, and thus delivering, Catena to Canadian patients who are approved by Health Canada’s Special Access Programme (SAP). The price will remain about the same. Santhera can in no way influence...
February 27, 2013: Santhera Pharmaceuticals announced the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich’s Ataxia, and subsequent consultation with Health Canada.
Press Release Liestal, Switzerland, May 20, 2010 – Santhera Pharmaceuticals (SIX: SANN) announced today that its MICONOS Phase III study evaluating Catena®/Sovrima® for the treatment of Friedreich’s Ataxia missed its primary endpoint. Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera’s Phase...
